ism 2025 earnings deck en.pdf
2025 Full Year Earnings Call
March 2026
Today’s Agenda
- Company Strategy
- Business Highlights
- AI Platform
- Asset Pipeline
Company Strategy
Traditional drug R&D takes >10 years and >$2B*
Probability of Success %
Cycle time (years)
The Locus of AI Acceleration
The real AI impact is between Target Discovery and Preclinical Candidate (PCC),
beyond PCC stage is heavily regulated and standardized timeline.
Evaluating AIDD Companies Metrics to evaluate an AIDD company: The Potential → The Proof
- AI Productivity Index
- Algorithm Patents
- Compute Power
Insilico Medicine Stats
- 12-18 months Average time to PCC
- $3-5M Average cost to PCC
Leveraging the Flywheel Effect to Position Our AI Platform at the Forefront
PHARMA.AI Software Platform
Continuous improvement and expansion on capabilities and accuracy of PandaOmics, Generative Chemistry and AIchemistry etc.
2025
- Launched Nach01, MDFlow, MoISpace etc.
- Launched Model Training, Retrosynthesis, Generative Biologics, DORA etc.
2024
- Generated 1000+ benchmarks during PCC development.
Drug Discovery and Development
- Completed 1 Phase IIa trial
- 2 Phase II trial ongoing
- 7 Phase I trial ongoing
AI-based Drug Discovery: Greater Novelty, Lower Cost, Faster Pace, and Higher Success
Delivering high-quality, highly novel PCC in significantly reduced time and at lower cost by leveraging AI early in the generative phase to eliminate toxic or unstable compounds before physical synthesis.
Our Pipeline Targets Found in Aging Gene Sets and Aging Clocks
| Fibrosis | Oncology/IO | Immunology/IBD | Metabolic | CNS | Cardiovascular/CKD | |
|---|---|---|---|---|---|---|
| TNIK | ● | ○ | ○ | ○ | ○ | |
| PHD1/2 | ● | ○ | ● | |||
| QPCTL | ● | ○ | ||||
| NLRP3 | ○ | ● | ○ | ● | ||
| TEAD | ○ | ● | ○ | ○ |
Business Highlights
Pharma.AI – Continued Innovation and Upgrades
Delivered strong software revenue momentum and transformative advancements in Pharma.AI platform.
Major transformative advancements in 2025 and YTD 2026.
Pipeline Momentum – New PCC Nomination Fuel Growth & Clinical Progresses Build Confidence
- 6 PCC Nominated
- ISM3830 (CBLB)
- ISM5059 (NLRP3)
- ISM0676 (GIPR)
- ISM6166 (Pan-KRAS)
- Pipeline:
- Undisclosed (Nav1.8)
- Undisclosed (GLP-1R)
- Clinical Validation: Completed first-in-patient dosing in Ph1 trial for MEN2501/ISM9682 (KIF18A)
- ISM8969 (NLRP3): Received IND approval from FDA for Ph1 trial.
AI Platform
Science MMAI Gym: Boosting Biological and Chemical Intelligence
- 6 Scientific Domains: Chemistry, Biology, Clinical, Aging/Longevity, Materials Science, Agriculture.
- 500M+ Data Samples across diverse curated data sources.
Foundation Model Training Routine
Baseline Performance Science Benchmarks across all therapeutic areas.
Asset Pipeline
~30 Asset Pipeline Discovered from Our Generative AI Platform with an Asset Most Advanced Globally among Peer Companies
| Stage of Development | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Target | Indication | Target Identification | Target-to-hit | Hit-to-lead | Lead Optimization | IND-enabled | Phase 1 | Phase 2 | Phase 3 | Partners |
| TNIK | IPF | China (NMPA) | China Phase IIa Completed | |||||||
| IPF (Inhalable) | US (FDA) | |||||||||
| IBD | China (NMPA) | Australia & China Phase I Completed | ||||||||
| PHD1/2 | Anemia of Chronic Kidney Disease | China (NMPA) | Greater China rights out-licensed to TaiGen | |||||||
| USP1 | BRCA-mutant Cancer | US (FDA) | POXUN PHARMA | |||||||
| ... |
Business Model
Multi-Pronged Revenue Generating Business Model for Long-term Growth
- Generated ~30 asset pipeline.
- 10+ out-licensing or collaboration deals with total contract value of >US$4.6 billion.
- Collaborated with 75 customers for drug discovery business in 2025.
Financials
Income Statement and Cash Position
| Year ended December 31 | ||
|---|---|---|
| 2024 USD'000 | 2025 USD'000 | |
| Revenue | 85,834 | 56,239 |
| Cost of revenue | (8,257) | (10,391) |
| Gross Profit | 77,577 | 45,848 |
| Selling and marketing expenses | (5,532) | (6,328) |
| Research and development expenses | (91,895) | (81,379) |
| Administrative expenses | (17,487) | (17,416) |
| Loss before tax | (16,935) | (352,256) |
2026 Key Milestones Across both the Platform and Therapeutic Pipeline
- ISM6331 (TEAD) preliminary safety, efficacy, and biomarker data from Ph1 trial.
- Rentosertib (Inhalable) IND approval for the treatment of IPF in China.
- Continue to execute MMAI Gym collaborations.
- Continue to achieve new BD deals.